Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes

Rita Sofia Garcia Ribeiro,1,* Sarah Belderbos,1,* Pierre Danhier,2 Juan Gallo,2 Bella B Manshian,1 Bernard Gallez,2 Manuel Bañobre,3 Marcel de Cuyper,4 Stefaan J Soenen,1 Willy Gsell,1 Uwe Himmelreich11Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Biomedical Sciences Group,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Garcia Ribeiro RS, Belderbos S, Danhier P, Gallo J, Manshian BB, Gallez B, Bañobre M, de Cuyper M, Soenen SJ, Gsell W, Himmelreich U
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	tumor targeting SKOV-3 cRGD magnetoliposomes MRI FLI Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9f2dd10528b542a08b999739827293ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f2dd10528b542a08b999739827293ad
record_format	dspace
spelling	oai:doaj.org-article:9f2dd10528b542a08b999739827293ad2021-12-02T08:07:03ZTargeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes1178-2013https://doaj.org/article/9f2dd10528b542a08b999739827293ad2019-07-01T00:00:00Zhttps://www.dovepress.com/targeting-tumor-cells-and-neovascularization-using-rgd-functionalized--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Rita Sofia Garcia Ribeiro,1,* Sarah Belderbos,1,* Pierre Danhier,2 Juan Gallo,2 Bella B Manshian,1 Bernard Gallez,2 Manuel Bañobre,3 Marcel de Cuyper,4 Stefaan J Soenen,1 Willy Gsell,1 Uwe Himmelreich11Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Biomedical Sciences Group, Leuven B-3000, Belgium; 2Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique De Louvain, Brussels B-1200, Belgium; 3Diagnostic Tools and Methods/Advanced (Magnetic) Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory (INL), PT-Braga 4715-330, Portugal; 4Laboratory of Bionanocolloids, Interdisciplinary Research Centre, KULAK/KU Leuven, Kortrijk B-8500, Belgium*These authors contributed equally to this workPurpose: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the potential of MLs targeting the αvβ3 integrin overexpressed on tumor neovascularization and different tumor cell types, including glioma and ovarian cancer.Methods: MLs functionalized with a Texas Red fluorophore (anionic MLs), and with the fluorophore and the cyclic Arginine-Glycine-Aspartate (cRGD; cRGD-MLs) targeting the αvβ3 integrin, were produced in-house. Swiss nude mice were subcutaneously injected with 107 human ovarian cancer SKOV-3 cells. Tumors were allowed to grow for 3 weeks before injection of anionic or cRGD-MLs. Biodistribution of MLs was followed up with a 7T preclinical magnetic resonance imaging (MRI) scanner and fluorescence imaging (FLI) right after injection, 2h, 4h, 24h and 48h post injection. Ex vivo intratumoral ML uptake was confirmed using FLI, electron paramagnetic resonance spectroscopy (EPR) and histology at different time points post injection.Results: In vivo, we visualized a higher uptake of cRGD-MLs in SKOV-3 xenografts compared to control, anionic MLs with both MRI and FLI. Highest ML uptake was seen after 4h using MRI, but only after 24h using FLI indicating the lower sensitivity of this technique. Furthermore, ex vivo EPR and FLI confirmed the highest tumoral ML uptake at 4 h. Last, a Perl’s stain supported the presence of our iron-based particles in SKOV-3 xenografts.Conclusion: Uptake of cRGD-MLs can be visualized using both MRI and FLI, even though the latter was less sensitive due to lower depth penetration. Furthermore, our results indicate that cRGD-MLs can be used to target SKOV-3 xenograft in Swiss nude mice. Therefore, the further development of this particles into theranostics would be of interest.Keywords: tumor targeting, SKOV-3, cRGD, magnetoliposomes, MRI, FLIGarcia Ribeiro RSBelderbos SDanhier PGallo JManshian BBGallez BBañobre Mde Cuyper MSoenen SJGsell WHimmelreich UDove Medical Pressarticletumor targetingSKOV-3cRGDmagnetoliposomesMRIFLIMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 5911-5924 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	tumor targeting SKOV-3 cRGD magnetoliposomes MRI FLI Medicine (General) R5-920
spellingShingle	tumor targeting SKOV-3 cRGD magnetoliposomes MRI FLI Medicine (General) R5-920 Garcia Ribeiro RS Belderbos S Danhier P Gallo J Manshian BB Gallez B Bañobre M de Cuyper M Soenen SJ Gsell W Himmelreich U Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
description	Rita Sofia Garcia Ribeiro,1,* Sarah Belderbos,1,* Pierre Danhier,2 Juan Gallo,2 Bella B Manshian,1 Bernard Gallez,2 Manuel Bañobre,3 Marcel de Cuyper,4 Stefaan J Soenen,1 Willy Gsell,1 Uwe Himmelreich11Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Biomedical Sciences Group, Leuven B-3000, Belgium; 2Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique De Louvain, Brussels B-1200, Belgium; 3Diagnostic Tools and Methods/Advanced (Magnetic) Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory (INL), PT-Braga 4715-330, Portugal; 4Laboratory of Bionanocolloids, Interdisciplinary Research Centre, KULAK/KU Leuven, Kortrijk B-8500, Belgium*These authors contributed equally to this workPurpose: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the potential of MLs targeting the αvβ3 integrin overexpressed on tumor neovascularization and different tumor cell types, including glioma and ovarian cancer.Methods: MLs functionalized with a Texas Red fluorophore (anionic MLs), and with the fluorophore and the cyclic Arginine-Glycine-Aspartate (cRGD; cRGD-MLs) targeting the αvβ3 integrin, were produced in-house. Swiss nude mice were subcutaneously injected with 107 human ovarian cancer SKOV-3 cells. Tumors were allowed to grow for 3 weeks before injection of anionic or cRGD-MLs. Biodistribution of MLs was followed up with a 7T preclinical magnetic resonance imaging (MRI) scanner and fluorescence imaging (FLI) right after injection, 2h, 4h, 24h and 48h post injection. Ex vivo intratumoral ML uptake was confirmed using FLI, electron paramagnetic resonance spectroscopy (EPR) and histology at different time points post injection.Results: In vivo, we visualized a higher uptake of cRGD-MLs in SKOV-3 xenografts compared to control, anionic MLs with both MRI and FLI. Highest ML uptake was seen after 4h using MRI, but only after 24h using FLI indicating the lower sensitivity of this technique. Furthermore, ex vivo EPR and FLI confirmed the highest tumoral ML uptake at 4 h. Last, a Perl’s stain supported the presence of our iron-based particles in SKOV-3 xenografts.Conclusion: Uptake of cRGD-MLs can be visualized using both MRI and FLI, even though the latter was less sensitive due to lower depth penetration. Furthermore, our results indicate that cRGD-MLs can be used to target SKOV-3 xenograft in Swiss nude mice. Therefore, the further development of this particles into theranostics would be of interest.Keywords: tumor targeting, SKOV-3, cRGD, magnetoliposomes, MRI, FLI
format	article
author	Garcia Ribeiro RS Belderbos S Danhier P Gallo J Manshian BB Gallez B Bañobre M de Cuyper M Soenen SJ Gsell W Himmelreich U
author_facet	Garcia Ribeiro RS Belderbos S Danhier P Gallo J Manshian BB Gallez B Bañobre M de Cuyper M Soenen SJ Gsell W Himmelreich U
author_sort	Garcia Ribeiro RS
title	Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_short	Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_full	Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_fullStr	Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_full_unstemmed	Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_sort	targeting tumor cells and neovascularization using rgd-functionalized magnetoliposomes
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/9f2dd10528b542a08b999739827293ad
work_keys_str_mv	AT garciaribeirors targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT belderboss targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT danhierp targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT galloj targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT manshianbb targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT gallezb targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT banobrem targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT decuyperm targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT soenensj targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT gsellw targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes AT himmelreichu targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
_version_	1718398676307542016

Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes

Ejemplares similares